Fineline Cube

Follow:
14691 Articles
Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review
CompanyDeals

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology
CompanyDeals

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset
CompanyDeals

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson's Disease
CompanyDeals

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson’s Disease

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases
CompanyDeals

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene's GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population
CompanyDrug

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene’s GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population

Centergate's Subsidiary Shandong Huasu Receives NMPA Clinical Trial Approval for BDB Tablets – Novel Combination Antihypertensive Enters Clinical Development
CompanyDrug

Centergate’s Subsidiary Shandong Huasu Receives NMPA Clinical Trial Approval for BDB Tablets – Novel Combination Antihypertensive Enters Clinical Development

Zhongsheng's ZSP1601 Granted Breakthrough Therapy Designation by China's CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review
CompanyDrug

Zhongsheng’s ZSP1601 Granted Breakthrough Therapy Designation by China’s CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review

GeneScience's GenSci155 Wins NMPA Clinical Trial Approval – Long‑Acting IGF‑1 Analog Targets Bronchopulmonary Dysplasia and Rare Growth Disorder
CompanyDrug

GeneScience’s GenSci155 Wins NMPA Clinical Trial Approval – Long‑Acting IGF‑1 Analog Targets Bronchopulmonary Dysplasia and Rare Growth Disorder

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization
CompanyDeals

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS "Non‑Degradative Molecular Glue" Inhibitor Advances into U.S. Clinical Trials
CompanyDrug

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS “Non‑Degradative Molecular Glue” Inhibitor Advances into U.S. Clinical Trials

Allist's Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive
CompanyDrug

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive